HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.

The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.

Advanced prostate cancer is difficult to treat and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment, said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinais Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow not stop or shrink -- tumor growth.

The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time, said Agus. Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... readers on the “beauty of protection”. Skin Health ... through USA Today within the markets of New York, ... reach an estimated 750,000 readers. Its digital counterpart will ... online content hubs. To read more the Skin Health ...
(Date:5/29/2015)... Shaila Jiwa, a physiotherapist from Burnaby ... stated in a new announcement that patients of urinary ... commonly seen as a tabooed topic to talk about ... like Shaila Jiwa try to encourage people to come ... is a condition that can be classified under two ...
(Date:5/29/2015)... University, the first cannabis college in America, will return to Las ... demanded Basic and Advanced Classic Seminars on June ... each day. Certification is available upon completion of the seminars and ... 14 from 12:00 pm to 6:00 pm. Both the seminars and ... Casino in downtown Las Vegas. , Seminar topics covered ...
(Date:5/29/2015)... 29, 2015 The Croatia Cosmetic ... a long-lasting impression on what modern dentistry options are ... on a mission to revolutionize the perception of a ... high-class Wellness & Spa. , The top dental ... successful medical tourism agencies and led by ...
(Date:5/29/2015)... 2015 Healthpointe’s electromyography and nerve ... Los Angeles County clinics including its newest clinic ... being offered at all Healthpointe locations throughout Southern ... Bernardino County. , As the muscles contract, ... electrical impulses throughout the body and dictate whether ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2Health News:Oaksterdam University to Host Educational Cannabis Seminars and Job Fair in Las Vegas June 12 to 15; Training For Those Wanting To Work in Legal Cannabis Industry 2Health News:Oaksterdam University to Host Educational Cannabis Seminars and Job Fair in Las Vegas June 12 to 15; Training For Those Wanting To Work in Legal Cannabis Industry 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
(Date:5/29/2015)... May 29, 2015  Haemonetics Corporation (NYSE: HAE ... Operating Officer, will present at the JMP Securities Life ... on June 23 rd , 2015 at 11:30am Eastern ... Davies, presentation live via webcast at: http://wsw.com/webcast/jmp27/hae ... HAE ) is a global healthcare company dedicated to ...
(Date:5/29/2015)... May 29, 2015 Amgen (NASDAQ: ... pivotal Phase 3, global, randomized, placebo-controlled trials evaluating ... of secondary hyperparathyroidism (SHPT) in patients with chronic ... the primary endpoint, demonstrating that a greater proportion ... a greater than 30 percent reduction in parathyroid ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
Cached News: